We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

106 hedge funds and large institutions have $563M invested in Karyopharm Therapeutics in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more capital invested

Capital invested by funds: $306M → $563M (+$256M)

60% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 25

14% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 21

3% more funds holding

Funds holding: 103 → 106 (+3)

0.69% more ownership

Funds ownership: 5.6% → 6.3% (+0.69%)

3% less call options, than puts

Call options by funds: $3.67M | Put options by funds: $3.78M

Holders
106
Holders Change
+3
Holders Change %
+2.91%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
40
Reduced
25
Closed
21
Calls
$3.67M
Puts
$3.78M
Net Calls
-$117K
Net Calls Change
-$3.89M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$54.7M
2
State Street
State Street
Massachusetts
+$18.3M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$15.4M
4
ECP
Elk Creek Partners
Colorado
+$11.5M
5
Millennium Management
Millennium Management
New York
+$11M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$24.2M
2
O
OrbiMed
New York
-$18.8M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.6M
4
CS
Candriam SCA
Luxembourg
-$7.9M
5
PAI
Palo Alto Investors
California
-$3.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Macquarie Group
26
Macquarie Group
Australia
$3.66M – – –
Charles Schwab
27
Charles Schwab
California
$3.31M +$359K +2,647 +13%
JGC
28
J. Goldman & Co
New York
$2.98M +$2.8M +20,639 New
SSA
29
Schonfeld Strategic Advisors
New York
$2.74M +$2.58M +19,007 New
Invesco
30
Invesco
Georgia
$2.69M +$2.53M +18,624 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$2.31M +$78.1K +576 +4%
ACP
32
Acuta Capital Partners
California
$2.29M +$2.15M +15,833 New
MOACM
33
Mutual of America Capital Management
New York
$2.15M -$11.3K -83 -0.6%
JP Morgan Chase
34
JP Morgan Chase
New York
$2.06M +$85.4K +630 +5%
Creative Planning
35
Creative Planning
Kansas
$1.96M +$1.84M +13,597 New
UBS Group
36
UBS Group
Switzerland
$1.96M +$1.82M +13,402 +7,404%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.96M -$839K -6,186 -31%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$1.89M +$1.78M +13,107 New
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$1.75M +$193K +1,427 +13%
Morgan Stanley
40
Morgan Stanley
New York
$1.58M +$447K +3,298 +43%
Citigroup
41
Citigroup
New York
$1.23M +$922K +6,800 +389%
PCA
42
Private Capital Advisors
Connecticut
$1.13M -$3.7M -27,310 -78%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$1.11M +$3.93K +29 +0.4%
ECM
44
ExodusPoint Capital Management
New York
$952K +$662K +4,880 +284%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$881K +$23.9K +176 +3%
Swiss National Bank
46
Swiss National Bank
Switzerland
$871K – – –
AllianceBernstein
47
AllianceBernstein
Tennessee
$851K -$278K -2,047 -26%
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$833K +$182K +1,346 +30%
Jacobs Levy Equity Management
49
Jacobs Levy Equity Management
New Jersey
$700K +$658K +4,853 New
BC
50
Birchview Capital
Vermont
$673K – – –
1
2
3 4 5

KPTI Hedge Fund Activity: Q3 2019 in Review

106 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2019, worth a combined $563M — up 84% from $306M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new KPTI positions and 21 closed out — a net gain of 3 holders — while 40 added to existing stakes and 25 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $54.7M. The largest seller was Wellington Management Group, cutting an estimated $24.2M.

  • 106 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2019, up from 103 in Q2 2019.
  • Funds reported $563M of Karyopharm Therapeutics stock for Q3 2019, up 84% quarter-over-quarter.
  • 24 funds opened new Karyopharm Therapeutics positions in Q3 2019 and 21 closed out, a net change of +3 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2019 was Avoro Capital Advisors, an estimated $54.7M added.
  • The largest Karyopharm Therapeutics seller in Q3 2019 was Wellington Management Group, an estimated $24.2M sold.

Based on aggregated 13F filings for Q3 2019.